stock price
note figur million except per share data factset wolf research estim
price march
report limit sole use client wolf research pleas refer disclosur section locat end report analyst
certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc
tabl content
summari reason avoid
reason
reason avoid
valuat estim revis
compani data factset wolf research llc
invest view initi coverag peer perform rate year-end price target
upsid organ growth technolog analyt research develop solut acceler
growth remain attract start deliv state target top-line acceler
follow merger legaci im health quintil think like increas medium-term revenu growth
guidanc hsd msd investor day june adjust ebitda growth solidli excess revenu
growth current revenu growth target compani clearli drive innov across drug
develop continuum util impress collect asset capabl meet biopharma sponsor need
time current find similar organ growth across cro group lower multipl stronger
yield view provid clearer path near-term out-performance without argu multipl expans
upcom catalyst beyond earn datapoint biotech fund trend biopharma certainli continu
differ vs consensu estim assum revenu growth ahead consensu
margin in-lin slightli higher share count leav ep line consensu
price pt base ebit target ev ebit multipl
multipl relative-basi near current level averag
upsid risk thesi organ growth rate acceler beyond expect multipl expans continu compani
larger value-cr
downsid risk thesi fund environ weaken biopharma develop outsourc slow
compani data factset wolf research llc
estim comparison
line guidanc consensu
margin line consensu
remain share repurchas
post alloc drive
revenu growth
pt base ebit target multipl
price target methodolog assum current ev ebit multipl remain unchang
target multipl assum trade multipl premium
averag premium modestli assum across cro group rel recent year
compani data factset wolf research llc
premium
averag wider premium vs cro group
rel recent year
compani data factset wolf research llc
ia rel ev ebit rel ev ebit rel ev ebit rel ev ebit ev ebit enterpris debt unconsolid equiti count rel price initi coverag peer perform
note total return reflect annual dividend yield compar year-end price target
compani data factset wolf research llc
ep bridg
ep bridg
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
reason avoid
reason
track record aggress capit deploy
reason avoid
small evalu iqv model
risk biotech slowdown
reason avoid
reason healthi spend backdrop
world-wide pharmaceut spend grown compound-annual-growth-rate sinc reach
research repres approxim spend develop make balanc
 spend expect grow annual next sever year provid healthi backdrop
reason avoid
reason healthi spend backdrop continu
 spend among largest biopharma compani project increas project
start
note among compani spend also came approxim higher leav
project
biopharma ventur capit fund rais decreas recent high still best quarter
record importantli capit spent sever quarter
compani data factset wolf research llc
consensuscurr consensu reason avoid
reason outsourc gain drive attract organ growth
outsourc clinic develop market believ grown recent year driven combin
healthi growth increas level outsourc
outsourc gain attribut two separ issu larg biopharma increas outsourc rate
 mix shift toward emerg biopharma compani outsourc much higher develop spend
approxim clinic develop spend believ outsourc leav room continu
outsourc gain particularli given emerg biopharma contribut innov expect increas
compani data factset wolf research llc
penetr reason avoid
reason differenti model may produc share gain
merger im health quintil iqvia lh acquisit covanc introduc new
approach key cro function made data strategi real world evid rwe key focu industri
summar iqv capabl span entir develop commerci cycl
also aggress move address key clinic trial issu protocol amend recruit challeng
compani question challeng legaci cro model cost plu arrang openli
embrac fixed-pric contract risk share deal compar histor norm
believ increas trial effici cost certainti biopharma sponsor translat market share gain
allow compani exceed overal industri fairli attract organ growth rate
compani data wolf research llc
reason avoid
reason track record aggress capit deploy
despit im health quintil deal technic merger balanc sheet compani quickli reorder
quickli resembl take-over fund mix debt stock
discuss slide took net leverag ebitda end gradual deliv
sinc combin compani net leverag deal announc
estim assum hold net debt rel flat delver approx annual ebitda growth
compani instead issu debt keep net leverag level would add approxim
spend capital-expenditure share repo million
op net debt issuanc million
compani data wolf research llc
debt issuanc reason avoid
reason medium term revenu guidanc may increas
novemb investor day issu medium-term financi guidanc includ msd revenu growth
ebitda growth rate revenu growth
follow acceler technolog analyt research develop solut organ growth think
like increas medium-term revenu guidanc hsd msd investor day june adjust
ebitda growth solidli excess revenu growth current revenu growth target
 consensu estim assum revenu grow ebitda grow revenu growth
iqv medium-term guidanc introduc investor day
compani data factset wolf research llc
guidewrconsensuswrconsensusrevenu growthmsd ebitda revenu ep growthdoubl defer debt adjust term reason avoid
reason avoid small evalu iqv model
recent book trend organ growth rate certainli trend head right direct think
earli declar victori iqv model
net book-to-bil remain well above-averag posit exceed market growth
compani data wolf research llc
reason avoid
reason avoid group valuat averag
note includ cro averag due signific company-specif valuat swing
compani data factset wolf research llc
ex ex reason avoid
reason avoid signific leverag
iqv leverag remain above-averag post merger compani priorit share repurchas
interest rate cap swap agreement notion valu cover compani
given remain exposur increas interest rate would increas interest expens
ep
iqv weight averag cost debt note almost iqv debt denomin
compani data factset wolf research llc
creditterm reason avoid
reason avoid war talent could restrict margin
given strong growth industri transfer skill experienc rel high turnov
recent histori past year manifest form modestli higher wage increas
gener downplay pressur wage point certainli highli special role acceler
would clearli repres risk margin
clinic research associ annual chang pay
bdo cro industri compens turnov design trend report
reason avoid
reason avoid risk biotech slowdown
emerg biotech biopharma becom increasingli import growth driver
driven signific rais realiti compani limit intern resourc
greater need outsourc compar larg pharma
therefor spent emerg biotech much valuabl spent larg pharma
keep function project in-hous
observ expect emerg biotech remain key driver innov prolong slowdown fund
trend would rais concern sustain recent organ growth
pwc moneytre wolf research llc
reason avoid
reason avoid biopharma adjac drug price
materi chang pharma econom result drug price reform effort would almost certainli rippl
effect across industri vendor potenti reduc invest look cost offset
 within biopharma space disrupt nt consolid vendor lt given potenti reduct
spend would occur otherwis across two stand-alone compani
howev note light recent spate deal cro made comment downplay potenti
disrupt possibl current backdrop would make easier util excess capac
compani data trump administr wolf research llc
valuat estim revis
price-to-earnings valuat absolut rel
ntm price-to-earnings multipl rel
compani data factset wolf research llc
forward p/erel price-to-earnings year year year year price-to-earnings year year year year ev ebit valuat absolut rel
ntm ev/ebit multipl rel
compani data factset wolf research llc
forward ev/ebitrel ev/ebit year year year year ev/ebit year year year year ev ebitda valuat absolut rel
ntm ev/ebitda multipl rel
compani data factset wolf research llc
compani data factset wolf research llc
compani data factset wolf research llc
compani data factset wolf research llc
compani data factset wolf research llc
compani data wolf research llc
capit alloc oper cfo
compani data factset wolf research llc
provid inform innov technolog solut contract research servic biotech medic devic
pharmaceut compani medic research govern agenc payer healthcar stakehold
across globe access million patient record provid insight
world pharmaceut measur sale employe oper countri
three oper segment follow technolog analyt solut research develop solut
contract sale medic solut
provid saa cloud applic enabl clinic commerci process
exampl includ clinic trial design plan site start-up patient consent content manag custom
real-world insight empow healthcar decision-mak process provid access unidentifi patient-level
data help client analyz treatment outcom cost
analyt consult servic consult client surround strateg decis regard commerci
oper function
project manag clinic monitor coordin conduct multi-sit phase ii-iv clinic trial solut
includ protocol design feasibl oper plan site start-up patient recruit clinic site
clinic trial support servic support requir servic data stream assist client collect
analyz report qualiti data evid obtain regulatori approv
servic offer includ solut strateg plan design virtual trial
servic includ health provid engag servic patient engag servic medic affair servic
wolf research llc compani report
bousbib chairman ceo join im health chairman ceo continu serv
capac merger establish iqvia bousbib previous held senior leadership posit unit
technolog corpor utc progress presid execut leadership
respons experi partner booz allen hamilton global manag
technolog consult firm
michael mcdonnel evp cfo join quintil cfo posit continu serv capac
follow merger establish iqvia mcdonnel previous cfo
time cfo mcg capit corpor echostar commun dishnetwork partner
 richard staub presid research develop solut join quintil
acquisit novella clinic serv presid ceo continu capac
post-merg novella quintil compani transit presid research develop solut
occupi role senior vice-president global busi develop
kevin knightli presid inform join firm post-merg im health
presid inform octob tenur im health serv senior
vice-president inform offer senior vice-president supplier manag progress
variou senior financi oper market gener manag role im
wolf research llc compani report
